CORRECTION -- Goliath Commences Drilling at New Gold-Copper Porphyry and High-Grade Gold Breccia Targets at Its Lucky Strike Property Near Terrace, British Columbia
August 21, 2023 08:48 ET
|
Goliath Resources Limited
TORONTO, Aug. 21, 2023 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Goliath Resources Limited (TSX-V: GOT) (OTCQB: GOTRF) (Frankfurt: B4IF), please note that a...
Goliath Commences Drilling at New Gold-Copper Porphyry and High-Grade Gold Breccia Targets at Its Lucky Strike Property Near Terrace, British Columbia
August 21, 2023 07:08 ET
|
Goliath Resources Limited
BULLSEYE GOLD-COPPER PORPHYRY – ~1,000 Metres Diamond Drilling, Highlights: The Bullseye porphyry is a drill ready target that shows all the right components for an extensive gold-copper porphyry...
Goliath Intercepts 23 Meters* of 21.08 g/t AuEq, Including 14 Meters* of 33.75 g/t AuEq at Surebet Golden Gate Feeder Zone, Golden Triangle, B.C
August 15, 2023 10:18 ET
|
Goliath Resources Limited
Drill Highlights: GD-23-157 is a 485 gram x meter AuEq hole (15.59 troy ounces gram meter AuEq) collared from Cliff Pad within the Golden Gate Feeder Zone that intercepted Visible Gold mineralization...
Second Visible Gold Hole Drilled From Cliff Pad at Goliath's Surebet Golden Gate Feeder Zone and 19.87 Meters* of Significant Mineralization, Golden Triangle, B.C.
July 24, 2023 07:00 ET
|
Goliath Resources Limited
Drill Hole GD-23-135 Highlights: Visible Gold has been intercepted at 60.91 meters within the Surebet Golden Gate Feeder Zone and is the second hole drilled from Cliff Pad in 2023 to contain...
American Oncology Network Announces List of Research Studies Presented at the ASCO 2023 Annual Meeting
June 06, 2023 12:42 ET
|
American Oncology Network
FORT MYERS, Fla., June 06, 2023 (GLOBE NEWSWIRE) -- American Oncology Network, LLC (AON) announced that six research papers, co-authored by AON physicians and the vice president of pharmacy...
Coherus Announces Positive Final Overall Survival Results of JUPITER-02 Phase 3 Trial Evaluating Toripalimab in Nasopharyngeal Carcinoma
June 05, 2023 17:30 ET
|
Coherus BioSciences, Inc.
– Toripalimab plus chemotherapy resulted in a 37% reduction in the risk of death, HR=0.63, versus chemotherapy alone, in nasopharyngeal carcinoma patients – – No treatments are approved for NPC in...
PDS Biotechnology Post-ASCO Conference Call Tomorrow, June 6, at 8 a.m. ET
June 05, 2023 14:52 ET
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., June 05, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...
Onconova Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology Annual Meeting
June 05, 2023 08:00 ET
|
Onconova Therapeutics, Inc.
NEWTOWN, Pa., June 05, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel...
Cancer Support Community and Equiva Health partner to create new industry standard for digital cancer support
June 02, 2023 15:01 ET
|
Cancer Support Community
WASHINGTON, June 02, 2023 (GLOBE NEWSWIRE) -- The Cancer Support Community (CSC), a nonprofit dedicated to uplifting and strengthening people impacted by cancer, has partnered with Equiva Health...
BioNTech and OncoC4 Present Positive Phase 1/2 Data for Antibody Candidate BNT316/ONC-392 in Hard-to-Treat NSCLC at ASCO
June 02, 2023 06:45 ET
|
BioNTech SE
BNT316/ONC-392 is a next-generation anti-CTLA-4 monoclonal antibody candidate jointly developed by BioNTech and OncoC4 as monotherapy or combination therapy in a range of solid tumor indications,...